Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.489
Neutral
RSI(14)
50.442
Neutral
STOCH(KDJ)(9,3,3)
23.779
Sell
ATR(14)
1.281
Low Volatility
CCI(14)
-106.931
Sell
Williams %R
94.459
Oversold
TRIX(12,20)
0.437
Sell
StochRSI(14)
0.000
Oversold
Search
Novo Nordisk A/S
NVOAdd to Watchlist
48.520USD
+0.330+0.68%
Market hours （ET）Quotes delayed by 15 min
163.19BMarket Cap
11.35P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.62%
5 Days
-4.09%
1 Month
+5.69%
6 Months
-22.08%
Year to Date
-4.70%
1 Year
-27.39%
Key Figures
48.360Open
48.930High
4.48MVolume
11.35P/E TTM
11.31P/E Dynamic
1.892Dividend TTM
0.13%Turnover Ratio
48.190Prev. Close
48.170Low
133.87MTurnover
11.14P/E Static
5.20P/B
3.90%Div Yield TTM
24.13%ROA
81.44052wk High
1.02Volume Ratio
14.65BNet Profit
3.36BShares
4.2743EPS TTM
0.79Beta
73.77%ROE
35.12052wk Low
1.58%Amplitude
85.96%Gross Margin
163.19BMarket Cap
0.92Reward/Risk
1.76%Risk Rate
TradingKey Stock Score of Novo Nordisk A/S
Currency: USD Updated: 2026-07-22Key Insights
Novo Nordisk A/S's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 50.01.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novo Nordisk A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative-
Novo Nordisk A/S Highlights
StrengthsRisks
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.54% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 46.70B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 50.19%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 50.19%.
Undervalued
The company’s latest PE is 11.27, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 332.82M shares, decreasing 0.81% quarter-over-quarter.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 7.39M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.19.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
50.013
Target Price
-2.85%
Upside Space
Novo Nordisk A/S News
Novo Nordisk Sues Eli Lilly for False Advertising: Weight-Loss Drug Data War Escalates, GLP-1 $100 Billion Market Fight Heats Up
TradingKey - Novo Nordisk (NVO) has officially filed a lawsuit in the U.S. District Court for the District of New Jersey, alleging that Eli Lilly’s (LLY) advertisements for its blockbuster weight-loss drug Zepbound and diabetes injection Mounjaro are misleading and violate federal and state laws concerning false advertising and unfair competition. The essence of the lawsuit is a data war between the two pharmaceutical giants over the multi-hundred-billion-dollar GLP-1 drug market, where the key weapon on the battlefield is a set of clinical comparison data alleged to be "outdated."
TradingKeyTue, Jul 21
Eli Lilly Zepbound Returns to CVS Formulary, Pre-Market Shares Rise as Much as 2%
TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.
TradingKeyThu, May 28
Eli Lilly Weight-Loss Drug Retatrutide Posts Impressive Data; Can Novo Nordisk Break Through After Falling Behind Again?
TradingKey - On May 21, Eastern Time, Eli Lilly announced the results of the pivotal Phase 3 clinical trial (TRIUMPH-1) for its next-generation weight-loss drug, Retatrutide. As the world's first "triple agonist" targeting GIP, GLP-1, and glucagon receptors, its efficacy data has comprehensively sur
TradingKeyMon, May 25
Hold or Diversify? Why This Forgotten Industry Deserves a Look
Recent market performance has been more than just strong
TradingKeyThu, May 14
Is Novo Nordisk Positioned for Recovery in 2026 Amid Rising Competition and AI Innovations?
TradingKey - Since 1923, Novo Nordisk (NVO) has thrived as a pharmaceutical company based in Denmark, primarily focusing on two business areas: Obesity and diabetes, and Rare Diseases.
TradingKeyMon, May 4
Cross-Sector Collaboration Between Pharma and AI. Novo Nordisk Joins Forces With OpenAI, Can It Regain Market Dominance in the Competition With Eli Lilly?
TradingKey - Danish pharmaceutical manufacturer Novo Nordisk (NOVO) stated on Tuesday that it will partner with OpenAI to deploy artificial intelligence across all aspects of its business, from drug discovery to manufacturing and commercial operations.
TradingKeyWed, Apr 15
Earnings Forecast
Analyst Rating
Based on
14
analysts
Hold
Current Rating
50.013
Target Price
-2.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
Novo Nordisk A/S
NVO
14
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
36
Indicators
Moving Average
Indicators
Value
Direction
MA5
49.796
Sell
MA10
49.625
Sell
MA20
49.132
Sell
MA50
46.270
Buy
MA100
42.710
Buy
MA200
47.261
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Novo Nordisk A/S Info
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Ticker SymbolNVO
CompanyNovo Nordisk A/S
CEODoustdar (Maziar Mike)
Websitehttps://www.novonordisk.com/
Shareholders
Related Instruments
+1.61%
+1.03%
-0.62%
+1.31%
+2.52%
+1.88%
+0.41%
-0.42%
+0.56%
+1.46%
+0.58%
-0.91%
-0.35%
-0.01%
0.00%
+0.03%
+7.32%
-0.56%
+1.04%Popular Instruments
51692.400
-571.600 (-1.09%)
28466.500
-533.600 (-1.84%)
7404.300
-99.900 (-1.33%)
15100.000
-46.000 (-0.30%)
65250.000
-1006.000 (-1.52%)
6217.100
-92.700 (-1.47%)
92.052
+5.722 (+6.63%)
320.240
-5.650 (-1.73%)
209.953
-2.107 (-0.99%)
4049.070
-80.910 (-1.96%)
FAQs
What is the current price of Novo Nordisk A/S (NVO)?
The current price of Novo Nordisk A/S (NVO) is 48.19.
What is the symbol of Novo Nordisk A/S?
The ticker symbol of Novo Nordisk A/S is NVO.
What is the 52-week high of Novo Nordisk A/S?
The 52-week high of Novo Nordisk A/S is 81.44.
What is the 52-week low of Novo Nordisk A/S?
The 52-week low of Novo Nordisk A/S is 35.12.
What is the market capitalization of Novo Nordisk A/S?
The market capitalization of Novo Nordisk A/S is 162.07B.
Is Novo Nordisk A/S (NVO) currently rated as Buy, Hold, or Sell?
According to analysts, Novo Nordisk A/S (NVO) has an overall rating of signal_hold, with a price target of 50.01.
What is the Earnings Per Share (EPS TTM) of Novo Nordisk A/S (NVO)?
The Earnings Per Share (EPS TTM) of Novo Nordisk A/S (NVO) is 3.48.